Since 2001, Dr. Shlomo Markel has been serving as Vice President at Broadcom Corp (since 2/2016 Broadcom Limited), a leading multinational fabless broadband communications semiconductor company. In his broad role in R&D, technology roadmap, M&A and investments, he reports to Dr. Henry Samueli, Broadcom’s co-founder & CTO. Dr. Markel also oversees Broadcom operations in Israel - in the last decade acquired 13 startup companies in Israel (9 in the last 5 years) growing Broadcom R&D centers in Israel to hundreds of engineers in 8 sites. After retiring from the Israeli Navy with a rank of R. Admiral, Chief of Material Command, overseeing all programs, R&D, logistics & engineering and serving in variety of advanced technology, programs and embedded computer systems’ engineering & commanding roles, Dr. Markel was Argoquest CTO, a US holding company with over 60 startup portfolios. Shlomo who holds a Technion PhD in EE was member of the Technion EC and is a member of the GoI D&O Nominee Committee.
President, Tel Aviv University
Professor Joseph (Yossi) Klafter was named President of Tel Aviv University in 2009, the eighth since TAU’s founding in 1956. Widely recognized in his field, chemical physics, he served as the chairman of the Israel Science Foundation (ISF), the main institution supporting scientific research in Israel, from 2002 to 2009.
Professor Klafter has published close to 400 scientific articles, edited 18 books and is the co-author of First Steps in Random Walks: From Tools to Applications (Oxford University Press, 2011). He has been a member of the editorial boards of numerous scientific journals and a member of the scientific committees of dozens of conferences.
In 2011, The American Academy of Arts and Sciences elected him an honorary member, and he is also a fellow of the American Physical Society. Professor Klafter has won many prestigious prizes in his field, including the Alexander von Humboldt Foundation Prize, the Weizmann Prize for Sciences, the Rothschild Prize in Chemistry, and the Israel Chemical Society Prize. He also holds an honorary doctorate from Wroclaw University of Technology, Poland.
Professor Klafter completed his BSc and MSc in physics at Bar-Ilan University, and his PhD in chemistry at Tel Aviv University. After post-doctoral studies in chemistry at MIT, he joined the research and engineering division of Exxon in the US, where he worked for eight years. He joined the TAU Raymond and Beverly Sackler School of Chemistry in 1987, and was promoted to full professor in 1989. From 1998 to 2003 he was the incumbent of the Gordon Chair in Chemistry, and from 2003 onward he has held the Heineman Chair of Physical Chemistry.
Prof. Klafter chaired the Department of Physical Chemistry at TAU from 1990 to 1992, and again from 1998 to 2002. Concurrently he served as head of the Raymond and Beverly Sackler Institute of Chemical Physics.
Dr. Yaron serves as Chairman of Tel Aviv University (Executive Council), and on the board of Amdocs (DOX). Dr Yaron serves on the advisory board of the Ministry of Defense.
Dr. Yaron is an active Founding Investor and Founder of a group of high-tech and med-tech companies; P-cube, (acquired by Cisco), PentaCom (acquired by Cisco), Qumranet (acquired by Redhat), Comsys (acquired by Conexant, Texas Instruments), Exanet (acquired by Dell) Hyperwise Security (acquired by Checkpoint) Qwilt, Itamar Medical, Excelero and Equalum. Dr. Yaron has been serving as board member and/or Chairman of the Boards of these companies since their inception.
Dr. Yaron served as Chairman of the Board of Mercury Interactive (acquired by HP).
From 1992-1995 Dr. Yaron has served as President of Indigo NV, leading the company to an NASDAQ IPO. Prior to joining Indigo served as corporate Vice President of National Semiconductor and was the Founder of National wafer fab in Israel (today Tower Semiconductors).
Dr. Yaron holds a Ph.D. in Device Physics from the Hebrew University has published numerous scientific papers and holds numerous patents.
Prof. Yoav Henis is TAU Vice President for Research and Development. In 1974 received his B.Sc. Cum Laude after completing his studies in Chemistry and Biochemistry at the Hebrew University. In 1978 he completed his doctoral thesis (direct course for Ph.D.) Summa Cum Laude at the Hebrew University, under the guidance of Prof. Alexander Levitzki. This thesis has won the Hebrew University Kennedy-Lee prize for the best thesis of the year. Between 1978 and 1981 he was a post-doctoral fellow (supported by Chaim Weizmann Fellowship from the Weizmann Institute) under the guidance of Prof. Elliot Elson, first at Cornell University (Ithaca, NY) and then at Washington University School of Medicine (St. Louis, MO). Upon his return to Israel in 1981 he became a Faculty member at the Department of Biochemistry, and then the Department of Neurobiology, in the George S. Wise Faculty of Life Sciences, Tel Aviv University.
In addition, Prof. Henis held visiting scholar positions at the M.I.T. (Whitehead Institute), Cambridge, MA (1987-8, 1992-3, 1998-9), the Lawrence Berkeley National Laboratory at Berkeley, CA (2003-4), and Duke University Medical Center, Durham, NC (2009-10).
Prof. Henis has served as the head of the Committee for acceptance of undergraduate students to the Faculty of Life Sciences (1985-7), the secretary of the Israel Society for Cell Biology (1991-5), the head of the Department of Neurobiochemistry (today named Neurobiology) (1995-8), and was a member in many University and National Committees.
Prof. Henis is one of the leaders in the Cancer Biophysics field. His studies combine cell biology with membrane biophysics to elucidate, in live cells, the action mechanisms of cancer-related proteins. These studies, which deal with the growth-inhibitory transforming growth factor- receptors and with oncogenic proteins such as Ras and Src, were published in scientific journals of high standing. He is active in scientific organizations in Israel and the USA, and was a member of numerous committees and scientific forums of the Israel Science Foundation and other scientific foundations in Israel. He has won prizes and fellowships from the Bat-Sheva de Rothschild Foundation, the International Union Against Cancer, and the Jacqueline Seroussi Memorial Foundation Award for Cancer Research.
Yair Aharonowitz, Ph.D., is a Professor (Emeritus) of Microbiology and Biotechnology at Tel Aviv University (TAU). After receiving his Ph.D from TAU, he was a research fellow in biochemical engineering at MIT (USA), and since 1976 he has become a member of the academic staff of TAU. He was a visiting scientist at Oxford University (UK), an Alberta Heritage Fellow at the University of Alberta, Edmonton, and a visiting professor at the Karolinska Institute (Sweden) and at the University of British Columbia, Vancouver, Canada. Professor Aharonowitz research interests include the molecular genetics and biosynthesis of antibiotics, molecular biology of microbial pathogens and the development of new targets for new antibiotics, thiol-disulfide redox metabolism and metabolic regulation at the transcription level by transcription factors and riboswitch mechanisms. He maintains close cooperation with the pharmaceutical industry and serves as a member of the BOD of Compugen. During his service at TAU Professor Aharonowitz held several senior positions, as TAU Vice President and Dean for R&D, Chairman of the Department of Microbiology and Biotechnology and Chairman of the Institute of Biotechnology. He was a member of Tel Aviv University Executive Council and of TAU Board of Governors.
Professor Aharonowitz served as the Cairman of Ramot Fund for Applied Research, as a member of TAU committee for strategic planning, in the TAU patent committee, he was a member of the National Committee for Biotechnology and served as a member of the Israel Prize committee (in the life sciences).
Professor Aharonowitz is a Fellow of the American Academy of Microbiology and a member of the Israeli Society of Microbiology.
Born in 1948, graduate of Economics from The Hebrew University, Jerusalem and an MBA from Tel Aviv University in Business Management.
1978 - 1994 - Held various positions within Tel Aviv University, most recently as Deputy General Manager, Faculty of Engineering.
1994 - 2007 - General Manager of the Academic College of Tel Aviv – Yaffo
2007 – present – CEO of Tel Aviv University
Senior Associate Provost and Chief Technology Development Officer, Harvard University
Isaac Kohlberg joined OTD in 2005, as Chief Technology Officer and Senior Associate Provost. Prior to joining Harvard, he served (from 1989 to 2000) as Vice Provost of New York University and Vice Dean for Industrial Liaison and Research Administration at the New York University School of Medicine. Most recently, Isaac was Chief Executive Officer of the Tel Aviv University Economic Corporation and CEO of RAMOT, its technology transfer organization. Isaac was also CEO of the YEDA Research and Development Company, the technology transfer company of the Weizmann Institute of Science, for eight years. He received his LLB from Tel Aviv University and his MBA from INSEAD, Fontainebleau, France.
Corporate Vice President Innovation
EMC Centers of Excellence and R&D Centers
GM Israel Center of Excellence
Dr. Orna Berry is a recognized entrepreneur with over 30 years of experience in the Israeli science, technology and venture capital industries. She is known for her efforts to promote excellence, entrepreneurship and innovation in Israeli society.
Dr. Berry has held a wide range of key positions with significant social and public impact throughout her career. She co-founded Ornet Data Communications Ltd, later acquired by Siemens; held the position of Chief Scientist of the Ministry of Industry and Trade in the Israeli government; served as the Chairperson of the Israeli Venture Capital Funds Association (IVA) and was a Venture Partner at Gemini Israel Funds.
In addition, Dr. Berry served as the Chairperson of several bi-national funds, the BIRD Foundation (USA), the CIIRDF (Canada), as well as Korea (KORIL) and Singapore (SIIRDF) funds. She also negotiated Israel’s participation in the EU research and technology funds, and served on the EU research Advisory board.
Dr. Berry has also held a number of managerial and scientific positions, a research fellow in Unisys and IBM and chief scientist and program manager in Fibronics. She has also served as chairman of the board at PrimeSense, later acquired by Apple.
Since 2011, Dr. Berry serves as Corporate Vice President of Innovation at EMC Centers of Excellence and R&D Centers, and General Manager of the Israel Center of Excellence. Since 2009, she is the Chairperson of the Israel-Australia Chamber of Commerce (IACC) and the chairperson of the Executive Committee of the Academic College Tel Aviv-Jaffa.
Throughout her career, Dr. Berry has been the recipient of various awards. In 2014, she received the "WITI Hall of fame" award, by WITI Women in Technology International. Every year, WITI recognize and honor the outstanding contribution women make in the scientific and technological communities around the world. In 2012 she was the recipient of the "Yakirat Ha'Negev" award from Ben Gurion University, which recognized her achievements and excellence in the technology industry, as well as her successful entrepreneurship ventures and profound involvement in establishing an EMC R&D branch in the Negev region.
In 2011 she was granted the Viterbi Award from the University of Southern California (USC) for her the ability to integrate entrepreneurship with professional excellence.
Mrs. Kaplinsky is a leading specialist in international business development within the healthcare and technology industries.
Moved by the innovative and resilient ability of Israeli start-ups to contribute to the world's most pressing challenges, Sharon was inspired to help accelerate the growth of Israeli technologies and connect them with the right global partners and investors- Star Tree Ventures was born.
Prior to founding Star Tree Ventures, Mrs. Kaplinsky managed the business development and strategic planning in Orphan Technologies Ltd, a company focused on research and development of innovative therapies for rare, life-threatening diseases with unmet medical needs. In this position, she conducted the due diligence on hundreds of early-stage healthcare products and led in-licensing transactions.
Prior to that, Mrs. Kaplinsky was an Associate Consultant at Defined Health, a leading Business Development consulting company in New Jersey, and was a Research Analyst at Science and Technology Ventures, the Technology Transfer Office of Columbia University.
Mrs. Kaplinsky holds a MA in Biotechnology from Columbia University and a B.Sc. Summa Cum Laude in Biology from Tel-Aviv University.
Tomer is the co-founder and Chief Executive Officer of Pontifax. He serves as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Tomer serves as the Chairman of Check-Cap and is a board member at Macrocure and V-Wave. During the 10 years prior to establishing Pontifax, he held senior management positions at top Israeli financial institutions, playing a key role in investing in, nurturing and managing technology driven startups. Tomer holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.
Prof. Gil Markovich is the head of the School of Chemistry at TAU. In 1996 he received a Ph.D. in Chemical Physics under the guidance of Prof. Ori Cheshnovsky and then moved to UCLA for post-doctoral research with Prof. James Heath. In 1998 he returned to TAU and established a lab to study the physical properties of colloidal inorganic nanomaterials. His expertise includes preparation and studies of magnetic nanocrystals, metal nanowire films and nanoscale chirality. In recent years several applied projects emerged out of his lab, several patents were registered and various cooperation projects with high-tech companies were initiated.
Ohad Finkelstein lead the international investment of Venrock (www.venrock.com) from 2005 -2011. He has an extensive background in the finance, technology, and telecom industries as well as in developing new companies, markets, and products globally; In 2011 Ohad co founded Crescent Point Lantern with offices in Singapore and Israel. His prior stint as Chairman, President, and CEO of the pan-European Interoute Telecom Group added to his previous experience as Senior Vice President International Sales and Vice President Global Operations for VocalTec Communications Ltd. Ohad has also held management positions at companies including Packard Bell Electronics in the U.S. and has served as a senior advisor for IDEA, a world leader in financial and economic analysis. In 2008, Ohad was named one of the 100 most influential people in telecom by Global Telecoms Business magazine.
Ohad holds bachelors degrees in Political Science and International Marketing from the University of California in Los Angels.
He is a member of the UK IOD (Institute of Directors).
He is a member of the Board of Directors of the Inter Disciplinary Center in Israel.
President and CEO, Compugen Ltd.
Dr. Cohen-Dayag joined Compugen in 2002, and has held the positions of Vice President Research and Development, Vice President Diagnostic Biomarkers & Drug Targets, and Director of Diagnostics. In 2009, Dr. Cohen-Dayag was appointed, together with Mr. Martin Gerstel, as co-CEO of Compugen. In 2010, Dr. Cohen-Dayag was appointed Compugen’s President and Chief Executive Officer. Prior to joining Compugen, she was head of Research & Development and a member of the executive management at Mindsense Biosystems. Dr. Cohen-Dayag holds a B.S. in Biology from Ben-Gurion University, and an M.S. in chemical immunology and a Ph.D. in cellular biology from the Weizmann Institute of Science. In addition, Dr. Cohen-Dayag is a director of Ramot at Tel Aviv University Ltd.
Nissim Darvish, M.D., Ph.D., is a Senior Managing Director at Orbimed. Nissim is a veteran of the lifescience industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Nissim spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received eight prizes and awards. Nissim has served on boards of multiple companies, including Inotek Pharmaceuticals Inc., SuperDimension, Vascular Biogenics and Inca Medical.
Aaron Mankovski is a Managing General Partner at Pitango Venture Capital. Previously he founded, and was a Managing General Partner, of Eucalyptus Ventures. Prior to founding Eucalyptus, he served as Corporate Vice President of Orbotech Ltd.(NASDAQ: ORBK). In addition, Aaron served as President and CEO of Orbotech Inc, HQ in Boston USA.
Aaron currently serves on the boards of: OptimalPlus, Kilopass Technology Inc., Compass-EOS, Kaminario and observer at Formlabs. Previously he served on the Board of Directors of Chromatis Networks (acquired by Lucent for $4.5 Billion).
Aaron is also the founder and former Chairmain ot HTIA, now IATI - Israel Advanced Technology Industries (formerly: IVA/HTIA)Aaron holds a B.Sc. in Computer Science and Statistics from Tel Aviv University and has also served as a pilot in the Israeli Air Force.